Special Issue

Advances Research on Nanomedicine

Message from the Guest Editor

The scope of this Special Issue includes, but is not limited to, the following topics:

Artificial Intelligence-Assisted Nanomedicine Synthesis
Exploring the integration of artificial intelligence in the design and production of nanomedicines to enhance efficiency and precision.
Nanomedicine in Oncology Therapies
Investigating the application of nanomedicines in cancer treatments, focusing on reactive oxygen species (ROS)-based therapies such as photodynamic therapy (PDT), radiodynamic therapy (RDT), radiodynamic therapy (RDT), and chemodynamic therapy (CDT).
Novel Nanomedicine Delivery Strategies
Exploring innovative methods for delivering nanomedicines to target tissues, including transdermal, intranasal, and interstitium routes.
Nanomedicine and Tumor Immunotherapy
Examining how nanomedicines can enhance the effectiveness of tumor immunotherapies, potentially improving immune system responses against cancer.

Guest Editor

Dr. Rongcheng Han

State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China

Deadline for manuscript submissions

30 September 2025

MDPI

Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/
biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).